THE INVESTOR

메뉴열기
August 26, 2019

HanAll Biopharma invests W5.6b in Roivant Sciences’ subsidiary

PUBLISHED : July 19, 2019 - 15:53

UPDATED : July 19, 2019 - 16:00

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

HanAll Biopharma, a subsidiary of Daewoong Pharmaceutical, invested 5.6 billion won ($4.76 million) in Switzerland-based biotech startup Roivant Sciences’ subsidiary Immunovant Sciences, according to industry sources on July 19.

In return, the Korean company gained a stake in Immunovant Sciences.

Industry sources viewed the move as a strategic investment, as HanAll’s drug candidate HL161, licensed out to Roivant, has been showing progress in development. 




HanAll recently received $10 million in milestone payment from the Switzerland-based biotech startup, as it entered the phase 2 clinical trial. HL161 works to block pathogenic antibody recycling that causes autoimmune disease.

In 2017, HanAll Biopharma signed a contract with Roivant Sciences to license out the drug candidate for a total of $452.5 million, with Roivant Sciences paying the Korean firm $30 million upfront.

Immunovant Sciences is a subsidiary of Roivant Sciences, which was established to co-develop HL161 with the Korean company. Currently, the Swiss company has exclusive rights to develop, produce and commercialize HL161 in North America, Latin America, the EU, Middle East and North Africa.

Founded in 1973, HanAll Biopharma was acquired by Daewoong Pharmaceutical in 2015 for 104.6 billion won. Daewoong is currently the biggest shareholder of HanAll Biopharma with a 30 percent stake.

By Song Seung-hyun (ssh@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
Publisher. Editor : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Yang Sung-jin
Title : The Investor|Date of registration : 2015.04.28
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0114|Business info
Gov’t registration No. Seoul 아04099
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.